Emmis Acquisition Quick Ratio (EMIS) starting from the second quarter 2026 to second quarter 2025, Financial Strength Trends, Rankings, Financial Ratios - CSIMarket
CSIMarket Company Name, Ticker, Industry, else..
 


• Quick Ratio
• Working Capital
• LT Debt to Equity
• Debt to Equity
• Leverage Ratio
• Tangible Leverage
• Interest Coverage
• Debt Coverage
• Work. Cap. Per Revenue
Emmis Acquisition Corp   (NASDAQ: EMIS)

Emmis Acquisition 's Quick Ratio

EMIS's quarterly Quick Ratio and Cash & cash equivalent, Current Liabilities growth


In the wake of the increase in Current Liabilities in the second quarter 2026, Quick Ratio fell to 5.72 above Emmis Acquisition Corp average.

Within Major Pharmaceutical Preparations industry 170 other companies have achieved higher Quick Ratio than Emmis Acquisition in second quarter 2026. While Quick Ratio total ranking in the second quarter 2026 has deteriorated compared to the prior quarter from 138 to 316.

Explain Quick Ratio?
How much Cash & cash equivalents EMIS´s has?
What are EMIS´s Current Liabilities?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

EMIS Quick Ratio (Jun 30 2026)
Q2		 (Mar 31 2026)
Q1		 (Dec 31 2025)
Q4		 (Sep 30 2025)
Q2		 (Jun 30 2025)
Q2
Y / Y Current Liabilities Change 261.18 % -94.91 % -99.78 % -99.66 % -99.84 %
Y / Y Cash & cash equivalent Change - -83.23 % -84.48 % -80.81 % -
Quick Ratio MRQ 5.72 15.64 43.67 18.63 -
EMIS's Total Ranking # 316 # 138 # 276 # #
Seq. Current Liabilities Change 147.77 % 130.34 % -72.03 % 126.3 % -96.51 %
Seq. Cash & cash equivalent Change -9.47 % -17.48 % -34.47 % - -



Quick Ratio second quarter 2026 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 171
Healthcare Sector # 276
Overall Market # 740


Quick Ratio Statistics
High Average Low
43.67 3.58 0.01
(Dec 31 2025)   (Mar 31 2013)




Financial Statements
Emmis Acquisition 's Current Liabilities $ 0 Millions Visit EMIS's Balance sheet
Emmis Acquisition 's Cash & cash equivalent $ 1 Millions Visit EMIS's Balance sheet
Source of EMIS's Sales Visit EMIS's Sales by Geography


Cumulative Emmis Acquisition 's Quick Ratio

EMIS's Quick Ratio for the trailling 12 Months

EMIS Quick Ratio

 (Jun 30 2026)
12 Months		 (Mar 31 2026)
12 Months		 (Dec 31 2025)
12 Months		 (Sep 30 2025)
12 Months		 (Jun 30 2025)
12 Months
Y / Y Current Liabilities TTM Growth -99.19 % -99.67 % -98.52 % -87.8 % -50.22 %
Y / Y Cash & cash equivalent TTM Growth -78.78 % -88.27 % -78.48 % -69.13 % -45.3 %
Quick Ratio TTM 14.22 17.3 6.32 1.13 0.54
Total Ranking TTM # 231 # 1463 # 1389 # 1839 #
Seq. Current Liabilities TTM Growth 48.79 % -83.56 % -89.68 % -68.06 % -38.27 %
Seq. Cash & cash equivalent TTM Growth 22.29 % -54.99 % -42.24 % -33.27 % -32.37 %

Quick ratio ranking by company, industry and sector >> Back to EMIS Financial Strength Comparisons >> Go to Compare EMIS Quick Ratio to its Competitors

On the trailing twelve months basis Due to in Current Liabilities in the Q2 2026 to $0.12 millions, cumulative Quick Ratio decreased to 14.22 above the EMIS average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 417 other companies have achieved higher Quick Ratio than Emmis Acquisition . While Quick Ratio overall ranking has improved so far to 0, from total ranking during the twelve months ending first quarter 2026 at 3555.

Explain Quick Ratio?
How much Cash & cash equivalents EMIS´s has?
What are EMIS´s Current Liabilities?

TTM Quick Ratio Company Ranking
Within: No.
Within the Major Pharmaceutical Preparations Industry # 418
Healthcare Sector # 852
Within the Market # 316


trailing twelve months Quick Ratio Statistics
High Average Low
6.28 0.64 0.04
(Mar 31 2026)   (Mar 31 2013)




Companies with similar Quick Ratio in the quarter ending Jun 30 2026, within Major Pharmaceutical Preparations Industry Quick RatioJun 30 2026 MRQ Cash & cash equivalentJun 30 2026 MRQ Current Liabilities
Telomir Pharmaceuticals Inc   15.55 $ 5.170  Millions$ 0.332  Millions
Rapport Therapeutics Inc   15.34 $ 436.077  Millions$ 28.424  Millions
Lb Pharmaceuticals Inc  15.32 $ 369.576  Millions$ 24.128  Millions
Anixa Biosciences Inc   15.09 $ 26.330  Millions$ 1.745  Millions
Siga Technologies Inc  14.99 $ 117.584  Millions$ 7.845  Millions
Vyne Therapeutics Inc   14.87 $ 22.925  Millions$ 1.542  Millions
Alto Neuroscience Inc   14.64 $ 243.733  Millions$ 16.652  Millions
Tenax Therapeutics Inc   14.62 $ 118.000  Millions$ 8.073  Millions
Jade Biosciences Inc   14.61 $ 461.205  Millions$ 31.570  Millions
Immunome Inc   14.56 $ 519.996  Millions$ 35.713  Millions
Sensei Biotherapeutics Inc   14.54 $ 186.441  Millions$ 12.824  Millions
Cytokinetics Incorporated  14.39 $ 2,610.415  Millions$ 181.429  Millions
Canton Strategic Holdings Inc   14.18 $ 37.242  Millions$ 2.626  Millions
An2 Therapeutics Inc   14.04 $ 78.387  Millions$ 5.585  Millions
Aclaris Therapeutics Inc   13.97 $ 394.443  Millions$ 28.241  Millions
Pmv Pharmaceuticals Inc   13.85 $ 146.393  Millions$ 10.568  Millions
Generate Biomedicines Inc   13.76 $ 779.456  Millions$ 56.636  Millions
First Tracks Biotherapeutics Inc   13.50 $ 168.018  Millions$ 12.447  Millions
Arrivent Biopharma inc   13.41 $ 373.401  Millions$ 27.844  Millions
Cogent Biosciences Inc   13.36 $ 792.300  Millions$ 59.296  Millions
Aprea Therapeutics Inc   13.33 $ 41.233  Millions$ 3.092  Millions
Polaryx Therapeutics Inc   13.22 $ 11.542  Millions$ 0.873  Millions
Monopar Therapeutics Inc   13.14 $ 52.758  Millions$ 4.016  Millions
Lexicon Pharmaceuticals Inc   12.96 $ 190.610  Millions$ 14.706  Millions
Korro Bio Inc   12.89 $ 162.805  Millions$ 12.628  Millions
Atea Pharmaceuticals Inc   12.89 $ 362.382  Millions$ 28.124  Millions
Oric Pharmaceuticals Inc   12.76 $ 264.761  Millions$ 20.756  Millions
Diamedica Therapeutics Inc   12.42 $ 81.875  Millions$ 6.594  Millions
Vtv Therapeutics Inc   12.35 $ 86.643  Millions$ 7.017  Millions
Theravance Biopharma inc   12.30 $ 378.546  Millions$ 30.766  Millions

Date modified: 2026-09-26T07:43:24+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.